Monomer Contains Oxygen Patents (Class 424/78.37)
-
Patent number: 8999302Abstract: Embodiments of a skin dye protectant formulation comprise at least about 30% by weight of a film forming composition, at least about 40% by weight of a solvent, water, at least 0.1% by weight of a dye, and at least about 1% to about 5% of antioxidants, wherein the formulation is operable to substantially maintain the color of the dye when the skin dye protectant formulation is subjected to gamma sterilization.Type: GrantFiled: October 22, 2009Date of Patent: April 7, 2015Assignee: Aplicare, Inc.Inventor: David Alan Childers
-
Publication number: 20150093353Abstract: Biomaterial compositions comprising extracellular matrix (ECM) and an ECM-mimicking biomaterial, such as poly(glycerol sebacate) (PGS), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions can also include additional biologically active agents, such as growth factors, and polymeric materials, such as polyepsilon-caprolactone (PCL).Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Inventor: Robert G. Matheny
-
Patent number: 8992945Abstract: A bio-adhesive supramacromolecular complex of the general formula: wherein R1 is independently selected from the group consisting of an alkane unsubstituted or substituted with alkoxy groups; R2 is independently selected from the group consisting of C1-6 alkyl; R3 and R4 are independently selected from the group consisting of optionally substituted aliphatic or aromatic alkyl; R5 is independently selected from the group consisting of H or C1-6 alkyl; W is a hydrogen-bond accepting functional group-containing entity; Y is a carboxylic acid ester or amide linkage; R is an independently selected peptide linking group; T1, T2, T3 and T4 are independently selected polymer residues; and m1, m2, m3, n1 and n2 are integers selected from at least 25; and wherein P has a molecular weight of about 1×103 to 1×107 and Q has a molecular weight of about 1×103 to 1×107. The complex provides controlled nitric oxide release over a longer period of time than prior art compounds in the locally delivery systems.Type: GrantFiled: August 20, 2008Date of Patent: March 31, 2015Assignee: University of TorontoInventors: Ping I. Lee, Yan Li
-
Publication number: 20150086504Abstract: The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C.Type: ApplicationFiled: December 1, 2014Publication date: March 26, 2015Inventors: Albertina Maria Eduarda Ariën, Marcus Eli Brewster, Aruna Nathan, Joel Rosenblatt, Louisa Myriam Ould-Ouali, Véronique Préat
-
Patent number: 8986724Abstract: Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided.Type: GrantFiled: June 21, 2013Date of Patent: March 24, 2015Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Thierry Glauser, Stephen D. Pacetti, Paul M. Consigny
-
Publication number: 20150079151Abstract: A composition comprising the reaction product of (a) an isocyanate group-containing component having an average functionality of at least 2; and (b) an active hydrogen group-containing component having an average functionality of at least 2. The composition is biodegradable, a solid at 22° C. and below, and has pressure sensitive adhesive properties at a temperature of 37° C. and relative humidity of 100%. The composition may be used to adhere polymer meshes or films to biological tissue.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Inventors: Eric J. Beckman, Jessica L. Meyers
-
Publication number: 20150079147Abstract: A fiber wadding for filling bone defects having a flocculent three-dimensional structure is disclosed. The fiber wadding includes a plurality of fibers that contain a biodegradable resin as a principal component and a siloxane. Outside diameter of the plurality of fibers of the wadding is from about 0.05 ?m to about 30 ?m. Bulk density of the fiber wadding is about 0.005-0.3 g/cm3.Type: ApplicationFiled: September 24, 2014Publication date: March 19, 2015Inventors: Toshihiro Kasuga, Akiko Obata, Kie Fujikura, Yoshio Ota, Xianfeng Yao
-
Patent number: 8961949Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).Type: GrantFiled: June 26, 2009Date of Patent: February 24, 2015Assignee: Japan Science and Technology AgencyInventors: Kazunori Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
-
Patent number: 8962676Abstract: The present invention is directed to the treatment of demyelination as an underlying cause of the disease of multiple sclerosis (MS) in a mammal, the method comprising promoting remyelination of myelination of axonal cells by administering to the mammal a 2-oxopyrrolidine compound having a general formula I: wherein R?R??H, and R??CH2CONH-(2,6CH3)C6H3 or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 22, 2010Date of Patent: February 24, 2015Assignee: University College Dublin, National University of Ireland, DublinInventors: Mark Pickering, Keith Murphy
-
Patent number: 8945610Abstract: The invention relates to a condensation product obtainable by reaction of a1) at least one bicyclic or polycyclic aromatic or heteroaromatic, where the bicyclic or polycyclic aromatic or heteroaromatic is substituted by at least one carboxyl group (—COOH), and where the carboxyl group can be present in salt form, a2) at least one carbonyl compound, a3) if appropriate at least one sulfonating agent, a4) at least one urea derivative, and a5) if appropriate at least one further aromatic or heteroaromatic, or a physiologically tolerable salt thereof.Type: GrantFiled: November 11, 2008Date of Patent: February 3, 2015Assignee: BASF SEInventors: Sebastien Garnier, Stephan Hüffer, Günter Scherr, Joachim Roser, Ulrich Mrowietz, Hans Wilhelm Doerr, Jindrich Cinatl, Martin Michaelis
-
Publication number: 20150030560Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: February 24, 2014Publication date: January 29, 2015Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Publication number: 20150024031Abstract: Disclosed herein are methods and pharmaceutical compositions for reducing the pain associated with parenterally administering a therapeutic agent. The methods and compositions comprise a dispersion comprising microparticles of an analgesic agent in an amount effective to reduce the pain, inflammation, and/or immunological reaction associated with parenterally administering a primary therapeutic agent, wherein the microparticles of the analgesic agent have an effective particle size of less than 20 micrometers.Type: ApplicationFiled: July 16, 2014Publication date: January 22, 2015Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Barrett Rabinow, Jane O. Werling
-
Publication number: 20150017115Abstract: Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed.Type: ApplicationFiled: March 5, 2013Publication date: January 15, 2015Inventors: Ronit Satchi-Fainaro, Ela Markovsky, Hemda Baabur-Cohen
-
Publication number: 20150017117Abstract: The present invention relates to a biocompatible polymer composition, suitable for in vivo vessel repair, comprising a matrix pre-polymer, a filler and a curing agent, wherein said composition wherein said biocompatible polymer composition is curable in the presence of a curing catalyst at 37° C. to form a cured material with an elongation until rupture of at least 5% and an elastic modulus of at least 1 MPa.Type: ApplicationFiled: December 7, 2012Publication date: January 15, 2015Inventor: Alexander Cornelis de Vries
-
Patent number: 8932611Abstract: The present invention relates to a solid anhydrous cosmetic composition comprising at least one non-spherical silicone elastomer and at least one silicone elastomer powder coated with a silicone resin. The invention also relates to a makeup process comprising the application to keratin materials of the said composition, and also to its use for obtaining a uniform makeup result that shows good fastness of the color over time.Type: GrantFiled: October 12, 2007Date of Patent: January 13, 2015Assignee: L'OrealInventors: Agnès Themens, Maïtena Leuridan
-
Publication number: 20150010492Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.Type: ApplicationFiled: May 1, 2014Publication date: January 8, 2015Applicant: National Jewish HealthInventors: Jerry A. Nick, Quinn M. Parks
-
Publication number: 20150010631Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.Type: ApplicationFiled: March 13, 2014Publication date: January 8, 2015Applicant: Cour Pharmaceuticals Development CompanyInventor: Daniel GETTS
-
Patent number: 8926955Abstract: The present invention relates to a process for the preparation of polymer conjugates of indolocarbaxole compounds, in particular of polymer conjugates of K-252a and derivatives thereof, by a synthetic route which results in a highly pure product, with a high product yield. In a further aspect the present invention relates to novel polymer conjugates of K-252a and derivatives thereof, wherein the chemical group linking the polymer unity to the K-252a or to the K-252a derivative compound is characterized by a 5-member oxazolidindionic cyclic structure. These novel polymer conjugates are obtained through the novel synthetic route with high purity and high yields.Type: GrantFiled: December 22, 2009Date of Patent: January 6, 2015Assignee: Creabilis S.A.Inventors: Raffaella Bagnod, Luca Beccaria, Luisa Bertarione Rava Rossa, Domenico Criscuolo, Chiara Lorenzetto, Valentina Mainero, Alessandra Marconi, Carlo Pincelli, Silvio Traversa
-
Patent number: 8920789Abstract: The invention provides method for sequestering or trapping L-lactate in or near a tumor cell comprising contacting an isolated polymer of D-lactic acid (PDLA) or an equivalent, derivative or analog thereof with the tumor cell so that the PDLA binds L-lactate in or near the cell and thereby sequestering or trapping L-lactate in or near the tumor cells.Type: GrantFiled: January 27, 2012Date of Patent: December 30, 2014Assignee: The United States of America as represented by the Department of Veterans AffairsInventors: Joel S. Goldberg, Joe Brice Weinberg
-
Patent number: 8921448Abstract: A low toxicity, highly efficient transfection composition is described with an amphipathic compound containing at least one imidazole. The composition may be used in the process of transfecting nucleic acids into an animal cell.Type: GrantFiled: July 16, 2010Date of Patent: December 30, 2014Assignee: Mirus Bio LLCInventors: Shannon E. Bruse, Laura K Juckem, Karen M Neder
-
Patent number: 8916143Abstract: The present disclosure provides injectable synthetic and biodegradable polymeric biomaterials that effectively prevent seroma, a common postoperative complication following ablative and reconstructive surgeries. Provided biomaterials include physically crosslinked hydrogels that are thixotropic, display rapid chain relaxation, are easily extruded through narrow gauge needles, biodegrade into inert products, are well tolerated by soft tissues, and effectively prevent seroma in a radical breast mastectomy animal model.Type: GrantFiled: November 3, 2009Date of Patent: December 23, 2014Assignee: Cornell UniversityInventors: David Putnam, Peter Zaweneh, Jason Spector
-
Publication number: 20140369954Abstract: The disclosed subject matter can provide a nanotube-reinforced polymer composite material comprising a plurality of nanotubes, each nanotube being formed of a plurality of cyclic peptide molecules, disposed within a polymer matrix, such as a biodegradable polymer matrix. A cyclic polymer, such as a cyclic 8-mer, composed of amino acid residues of alternating absolute configurations (D/L, R/S), can self-assemble into nanotubes useful for preparation of the composite polymer material of the invention. For example, the cyclic peptide (QL)4, wherein the glutamine and leucine residues are of opposite absolute configuration, self-assembles into nanotubes, which when formed into a reinforced polymer composite including poly(caprolactone), provides a biocompatible material of greater tensile strength and Young's modulus compared to the poly(caprolactone) material alone. The nanotubes can be prepared by a vapor equilibration technique or by a solvent-nonsolvent precipitation technique.Type: ApplicationFiled: November 26, 2012Publication date: December 18, 2014Applicant: President and Fellows of Harvard CollegeInventors: Neel Satish Joshi, Daniel James Rubin
-
Patent number: 8911720Abstract: The present invention is directed to a novel biocompatible polymer that may be used in tissue engineering. More specifically, the specification describes methods and compositions for making and using a citric acid copolymers.Type: GrantFiled: August 28, 2012Date of Patent: December 16, 2014Assignee: Northwestern UniversityInventors: Guillermo Ameer, Jian Yang, Antonio Roy Webb
-
Publication number: 20140363393Abstract: A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent includes an endogenously or exogenously supplied catalyst (other than catalase), or both, and/or the polymer or polymer-forming component.Type: ApplicationFiled: August 25, 2014Publication date: December 11, 2014Applicant: MATERIALS MODIFICATION, INC.Inventors: Joseph G. MONTES, Krishnaswamy Kasthuri RANGAN, Ramachandran RADHAKRISHNAN, Tirumalai Srinivas SUDARSHAN
-
Publication number: 20140363392Abstract: The present invention relates to an osteoinductive coating for use in dental implants, which can be obtained using a sol-gel process from methyltrimethoxysilane (MTMOS) as a silicon base precursor, ethyl tetraorthosilicate (TEOS) as a hydrophilic silicon precursor and at least one silicon precursor selected from glycidoxypropyltrimethoxysilane and aminopropyltrimethoxysilane. The invention also relates to the method for obtaining said coating and to the use thereof in dental implants.Type: ApplicationFiled: January 25, 2013Publication date: December 11, 2014Inventors: Julio Jose Suay Anton, Miriam Hernandez Escolano, Isabel Goni Echave, Maria Dolores Gurruchaga Torrecilla
-
Publication number: 20140356316Abstract: The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.Type: ApplicationFiled: February 24, 2011Publication date: December 4, 2014Applicant: RELYPSA, INC.Inventors: Eric Connor, Kalpesh Biyani, Scott Hecker, Inez Lees, Grace Huynh, Faleh Salaymeh, Hongmin Zhang, David Bergbreiter, Paul Mansky, YongQi Mu, Michael James Cope, Elizabeth Goka, Angela Lee, Deidre Madsen, Jun Shao, Xinnan Zhang
-
Patent number: 8900562Abstract: The present invention provides semi-fluorinated block copolymers and related methods of synthesizing and using semi-fluorinated block copolymers for drug delivery and drug formulation applications. Semi-fluorinated block copolymers of this aspect of the invention include block copolymers having discrete hydrophilic, fluorophilic and hydrophobic structural domains that are capable of forming supramolecular structures in aqueous solutions, such as micelles, for encapsulating hydrophobic and/or fluorophilic therapeutic agents. Encapsulation by semi-fluorinated block copolymers of the present invention allows for enhanced solubilization and stabilization of hydrophobic and/or fluorophilic therapeutic agents relative to conventional drug delivery compositions and methods.Type: GrantFiled: January 10, 2008Date of Patent: December 2, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Sandro Mecozzi, Glen S. Kwon
-
Publication number: 20140328933Abstract: Nanoparticles comprising VIP and their use in treating, e.g. pulmonary hypertension. Such nanoparticles provide improved delivery of VIP and allow for acute treatment and optionally for sustained release of VIP in a patient.Type: ApplicationFiled: June 16, 2011Publication date: November 6, 2014Inventor: Shaker Mousa
-
Publication number: 20140328919Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: December 17, 2013Publication date: November 6, 2014Applicant: CERULEAN PHARMA INC.Inventors: Jerry Zhang, Pei-Sze Ng
-
Publication number: 20140328915Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: June 19, 2014Publication date: November 6, 2014Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Publication number: 20140322158Abstract: A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-? concentration, BDNF concentration, caspase-1 concentration, IL-10/IL-18 ratio and IL-10/IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramerType: ApplicationFiled: April 30, 2014Publication date: October 30, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Suhayl Dhib-Jalbut
-
Publication number: 20140314705Abstract: The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Scott Whitcup, Orest Olejnik
-
Publication number: 20140314707Abstract: Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Alexander Andrianov, Alexander Marin
-
Publication number: 20140314706Abstract: A hemostatic putty for treatment of a variety of wounds topographies, including but not limited to highly three dimensional wounds, for example gunshot wounds and impalements, is disclosed. The putty is comprised of a matrix polymer weakly crosslinked or not crosslinked such that a viscoelastic matrix is formed. The viscoelastic nature of the putty is tunable by the composition and enables the putty to conform to a variety of wound topographies. Likewise, a hemostatic polymer, for example chitosan or hydrophobically modified chitosan, is included in this matrix to impart hemostatic properties and tissue adhesive on the putty. The hemostatic polymers disclosed prevent microbial infection and are suitable for oxygen transfer required during normal wound metabolism.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicant: University of Maryland, Office of Technology CommercializationInventors: Kevin Diehn, Matthew Dowling, Srinivasa R. Raghavan, David R. King
-
Patent number: 8865149Abstract: Polymeric reagents comprising a polymer attached, either directly or through one or more atoms, to a ketone or a related functional group such as ketone hydrate, thione, monothiohydrate, dithiohydrate, hemiketal, monothiohemiketal, dithiohemiketal, ketal, or dithioketal are provided. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.Type: GrantFiled: March 6, 2007Date of Patent: October 21, 2014Assignee: Nektar TherapeuticsInventors: Samuel P. McManus, Antoni Kozlowski, Xiaoming Shen, Daniel C. Cook
-
Patent number: 8858924Abstract: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.Type: GrantFiled: March 26, 2009Date of Patent: October 14, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: Josee Roy
-
Patent number: 8858917Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.Type: GrantFiled: January 9, 2009Date of Patent: October 14, 2014Assignee: President and Fellows of Harvard CollegeInventors: David A. Edwards, Howard A. Stone
-
Publication number: 20140301972Abstract: The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR? group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula —ROS03R? or —RNS03R? in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R? denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same.Type: ApplicationFiled: June 18, 2014Publication date: October 9, 2014Inventors: Denis BARRITAULT, Veronique Barbier-Chassefiere
-
Publication number: 20140301971Abstract: A medical composition and devices made from the composition for the delivery of extracts obtained from Boswellia genus, similar compounds synthetically derived, and in particular derivatives of triterpenes is disclosed. The medical device may be implantable, or alternatively a device which contacts the interior of a mammalian body. The medical device may be comprised, of or present an absorbable component containing Boswellia derivatives, or an eluting component. When administered into a particular body site, the Boswellia component may be released substantially and immediately, released slowly, or not released, into the body and residing actively on the medical device surface.Type: ApplicationFiled: June 21, 2012Publication date: October 9, 2014Inventors: Michael T. Milbocker, Lukas von Bluecher
-
Publication number: 20140301970Abstract: Gel-forming block copolymers were prepared comprising i) a central hydrophilic block consisting essentially of a divalent poly(ethylene oxide) chain and ii) two peripheral monocarbonate or polycarbonate hydrophobic blocks. The hydrophobic blocks comprise one or more vitamin-bearing subunits. The vitamin-bearing subunits comprise a carbonate backbone portion and a side chain comprising a covalently bound form of a vitamin. The gel-forming block copolymers can be used to prepare various biodegradable and/or biocompatible hydrogel and organogel drug compositions, in particular antimicrobial and/or anti-tumor drug compositions. The hydrogel compositions can be suitable for depot injections. Synergistic enhancement of toxicity to microbes was observed with compositions comprising an antimicrobial cationic polymer and an antimicrobial compound.Type: ApplicationFiled: April 9, 2013Publication date: October 9, 2014Applicants: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: James L. Hedrick, Ashlynn L. Z. Lee, Victor W. L. Ng, Yi Yan Yang
-
Patent number: 8852566Abstract: Compositions are provided for preferential distribution of active agents to injury sites. Such compositions may comprise a ligand with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature so that binding of the active agent to the delivery ligand and release of the active agent into the target site are not dependent on enzymatic activity. Methods of using such compositions are also disclosed.Type: GrantFiled: March 26, 2009Date of Patent: October 7, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Josee Roy, Toya Kimble
-
Patent number: 8840876Abstract: An antimicrobial composition comprising: a complex of an anionic polyester with an antimicrobial cationic surfactant, wherein the anionic polyester has at least one carboxylic group. A medical device having an antimicrobial composition comprising: a complex of an anionic polyester with an antimicrobial cationic surfactant wherein the anionic polyester has at least one carboxylic group.Type: GrantFiled: May 19, 2005Date of Patent: September 23, 2014Assignee: Ethicon, Inc.Inventors: Modesto Eemeta, Robert Di Luccio, Xintian Ming
-
Publication number: 20140271531Abstract: Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a lung at or near an alveolar duct targeted for reduction, occluding the airway and leading to tissue necrosis because the foam prevents oxygenation of the tissue surrounding the duct. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in-situ foam formation). In addition, the foam may form a seal, eliminating the source of air leaks.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: TOBY FREYMAN, MEGHAN MCGILL, GREGORY T. ZUGATES
-
Publication number: 20140271533Abstract: Systems and methods related to polymer foams for the treatment of blood vessel dissections are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to or within a dissection caused by an intimal tear in a blood vessel, sealing the dissection and preventing further perfusion thereof. In some embodiments, the polymer foam can be formed within a body cavity (i.e., in-situ foam formation). The foam may be used to fill the dissection as a thrombosing agent. In addition, the foam may be used in conjunction with medical devices such as stents, stent-grafts, balloons, and catheters.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Toby Freyman, Meghan McGill
-
Publication number: 20140271532Abstract: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.Type: ApplicationFiled: May 30, 2014Publication date: September 18, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Rivka Kreitman, Liat Hayardeny, Eran Blaugrund, Ruth Levy
-
Publication number: 20140271864Abstract: Individuals having diabetes are more prone to fractures, periodontitis, and other bone related issues as compared to healthy individuals. Furthermore, bone healing in diabetic patients is prolonged. The invention provides a method for decreasing bone resorption or increasing bone formation or promoting bone healing in diabetic patients. In particular, a biodegradeable polymer, such as a polyanhydride salicylate is administered at or near a bone defect site, and upon hydrolysis of the polymer will releases biologically active salicylic acid.Type: ApplicationFiled: March 18, 2014Publication date: September 18, 2014Applicants: The Trustees of the University of Pennsylvania, Rutgers, the State University of New JerseyInventors: Kathryn E. Uhrich, Dana Graves
-
Patent number: 8835492Abstract: Disclosed is a block copolymer formed by coupling the following components with each other: (a) a copolymer (A) of a polyethylene glycol (PEG) type compound with a biodegradable polymer; and (b) at least one oligomer (B) selected from the group consisting of poly(?-amino ester) and poly(amido amine). A method for preparing the same block copolymer, and a polymeric hydrogel type drug composition comprising the temperature and pH-sensitive block copolymer and a physiologically active substance that can be encapsulated with the block copolymer are also disclosed. The multiblock copolymer is obtained by copolymerization of a pH-sensitive poly(?-amino ester) and/or poly(amido amine) type oligomer, a hydrophilic and temperature-sensitive polyethylene glycol type compound and a hydrophobic and biodegradable polymer.Type: GrantFiled: March 31, 2006Date of Patent: September 16, 2014Assignee: Sungyunkwan University Foundation for Corporate CollaborationInventors: Doo Sung Lee, Min Sang Kim, Je Sun You, Huynh Dai Phu, Bong Sup Kim, Minh Khanh Nguyen
-
Publication number: 20140255336Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Inventors: Damien Kudela, Galen D. Stucky, Anna May-Masnou, Gary Bernard Braun, James H. Morrissey, Stephanie A. Smith
-
Publication number: 20140248233Abstract: An injectable composite material comprising a fibrous material comprised of a fir biocompatible low melting point polyester dispersed in a host medium comprised of second biocompatible low melting point polyester.Type: ApplicationFiled: February 8, 2012Publication date: September 4, 2014Applicant: The University of ManchesterInventors: Sandra Downes, Anita Kaur Bassi, Mohsen Zakikhani
-
Patent number: 8821910Abstract: The present application relates to oligomeric antimicrobial compounds and compositions comprising the same. The oligomers are formed by polymerizing aminoalkyl(meth)acrylate or aminoalkyl(meth)acrylamide monomer(s). In addition to imparting materials with broad spectrum antimicrobial activity, the oligomers can impart antimicrobial activity to substrates such as hair and skin.Type: GrantFiled: June 20, 2012Date of Patent: September 2, 2014Assignee: BASF SEInventors: Zhiqiang Song, Ted Deisenroth